Irisin/FNDC5 Antibody (936434) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: Flow
• Clone: 936434
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

Irisin/FNDC5 Antibody (936434) [Alexa Fluor® 350] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human Irisin/FNDC5
  Asp32-Glu143
  Accession # Q8NAU1
• Specificity: Detects human Irisin/FNDC5 in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Irisin/FNDC5 Antibody (936434) [Alexa Fluor® 350]

• fibronectin type III domain containing 5
• fibronectin type III domain-containing protein 5
• FNDC5
• FRCP2
• FRCP2Fibronectin type III repeat-containing protein 2
• Irisin

Background

Irisin (also known as FNDC5) is a 12 kDa glycosylated polypeptide hormone that regulates energy metabolism, stem cell differentiation, and neuronal development (1, 2). Human Irisin is synthesized as a 212 amino acid (aa) precursor encoding a type 1 transmembrane protein with a 121 aa extracellular domain (ECD), a 21 aa transmembrane domain, and a 39 aa cytoplasmic domain. The ECD of Irisin contains a fibronectin type III domain and multiple glycosylation sites. The ECD is proteolytically cleaved to release the 112 aa soluble Irisin hormone into circulation (2-5). Mature human, mouse, and rat Irisin share 100% sequence identity. Expression of Irisin is induced in skeletal muscle and subcutaneous adipose tissue during and shortly after exercise (2, 6). Irisin induces expression of peroxisome proliferator-activated receptor  gamma co-activator 1 alpha (PGC1 alpha ) and uncoupling protein-1 (UCP1), mitochondrial-associated metabolic proteins (7, 8). Irisin induces the transition of white adipose tissue into more metabolically active beige adipose tissue. In mice, expression of Irisin has been shown to regulate obesity and diabetes (1, 2). A similar function in humans is suggested (9). Irisin also regulates neuronal cell differentiation and neurite outgrowth in the brain and is involved in the differentiation of osteoblasts (10-14).

1. Bostrom, P. et al. (2012) Nature 481:463.
2. Novelle, M.G. et al. (2013) Int. J. Endocrinol. 2013:746281.
3. Ferrer-Martinez, A. et al. (2002) Dev. Dyn. 224:154.
4. Teufel, A. et al. (2002) Gene 297:79.
5. Zhang, W. et al. (2015) Neurosci. Lett. 595:7.
6. Roca-Rivada, A. et al. (2013) PLoS One 8:e60563.
7. Vaughan, R.A. et al. (2014) Diabetes Obes. Metab. 16:711.
8. Jeong Lee, H. et al. (2015) Mol. Endocrinol. 6:873.
9. Elsen, M. et al. (2014) J. Endocrinol. 222:R25.
10. Dun, S.L. et al. (2013) Neuroscience 240:155.
11. Forouzanfar, M. et al. (2015) Cell. Biol. Int. 39:629.
12. Hashemi, M.S. et al. (2013) Neuroscience 231:296.
13. Moon, H.S. et al. (2013) Metabolism 62:1131.
14. Colaianni, G. et al. (2014) Int. J. Endocrinol. 2014:902186.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q8NAU1()